Lupin Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Lupin Limited has informed the Exchange regarding a press release dated May 15, 2024, titled "Lupin Achieves Significant Milestone with ISO 14001 and ISO 45001 Certification Across All its Indian Manufacturing Sites, R&D Center and Corporate Office.".

Lupin Limited has informed the Exchange about Transcript of the Q4 FY2024 Earnings Conference call held on Tuesday, May 7, 2024.

Lupin Limited has informed the Exchange regarding Grant of 5000 Stock Options.

Lupin Limited has informed the Exchange regarding 'Re-launch of Mirabegron Extended-Release (ER) Tablets 25 mg in the United States.'.

Lupin Limited has informed the Exchange about audio recording of the Earnings Call - Q4 FY2024.

Lupin Limited has informed the Exchange about Investor Presentation Q4 FY 24.

Lupin Limited has informed the Exchange regarding Appointment of Mr. Alfonso Zulueta as Independent Director of the company w.e.f. May 06, 2024.

Lupin Limited has informed the Exchange regarding Appointment of Mr. Jeffrey Kindler as Independent Director of the company w.e.f. May 06, 2024.

LUPIN LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

Lupin Limited has informed the Exchange that Board of Directors at its meeting held on May 06, 2024, recommended Final Dividend of 400% i.e. Rs. 8 per equity share.

Lupin Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.

Lupin Limited has informed the Exchange about Loss of Share Certificates

LUPIN LIMITED has informed the Exchange about Loss of share certificates

Lupin Limited has informed the Exchange regarding Outcome of Board Meeting held on 06-May-2024 for Dividend

Lupin Limited has informed the Exchange regarding a press release dated May 06, 2024, titled "Lupin Q4 FY2024 Results".

Lupin Limited has informed the Exchange regarding a press release dated May 06, 2024, titled "Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP.".

Lupin Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.'.

Lupin Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.'.

Lupin Limited has informed the Exchange about Loss of Share Certificates